# Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

> **NCT04591002** · PHASE2 · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 43 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Osimertinib 80 MG

## Key facts

- **NCT ID:** NCT04591002
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-11
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591002, "Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04591002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*